Merck, Inc.
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
- Conditions
- Prostate CancerProstatic Neoplasms
- Interventions
- First Posted Date
- 2025-04-13
- Last Posted Date
- 2025-05-29
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1440
- Registration Number
- NCT06925737
- Locations
- 🇺🇸
St. Vincent Frontier Cancer Center-Research ( Site 0037), Billings, Montana, United States
🇺🇸Blue Ridge Cancer Care ( Site 0024), Roanoke, Virginia, United States
🇮🇱Rambam Health Care Campus ( Site 0462), Haifa, Israel
A Clinical Study of Belzutifan (MK-6482) Alone or With Phenytoin in Healthy Participants (CA46602/MK-6482-035)
- First Posted Date
- 2025-04-01
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 14
- Registration Number
- NCT06903715
- Locations
- 🇺🇸
Celerion, Inc. ( Site 0001), Tempe, Arizona, United States
A Study of Carbamazepine (CBZ) and MK-8527 in Healthy Adult Participants (MK-8527-012)
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 16
- Registration Number
- NCT06893081
- Locations
- 🇺🇸
Celerion ( Site 0001), Tempe, Arizona, United States
A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001)
- Conditions
- Malignant Neoplasm
- Interventions
- Biological: MK-4700
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 82
- Registration Number
- NCT06894771
- Locations
- 🇮🇱
Rambam Health Care Campus ( Site 0201), Haifa, Israel
🇮🇱Rabin Medical Center ( Site 0202), Petah Tikva, Israel
🇮🇱Sheba Medical Center ( Site 0200), Ramat Gan, Israel
A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)
- Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Interventions
- First Posted Date
- 2025-03-24
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 150
- Registration Number
- NCT06891066
- Locations
- 🇺🇸
Georgetown University Medical Center ( Site 4106), Washington, District of Columbia, United States
🇵🇷Ponce Medical School Foundation Inc./CAIMED Center ( Site 4301), Ponce, Puerto Rico
🇵🇷Clinical Research Puerto Rico ( Site 4300), San Juan, Puerto Rico
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- Conditions
- Lymphoma, Large B-Cell, Diffuse
- Interventions
- First Posted Date
- 2025-03-24
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 594
- Registration Number
- NCT06890884
- Locations
- 🇮🇱
Haddasah Medical Center ( Site 0601), Jerusalem, Israel
🇮🇱Sheba Medical Center ( Site 0603), Ramat Gan, Israel
A Clinical Study to Evaluate Enlicitide (MK-0616) Formulations in Healthy Adult Participants (MK-0616-035)
- First Posted Date
- 2025-03-18
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 40
- Registration Number
- NCT06880874
- Locations
- 🇺🇸
Celerion ( Site 0001), Tempe, Arizona, United States
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
- Conditions
- Castration-Resistant Prostatic CancerMetastasis
- Interventions
- First Posted Date
- 2025-03-07
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 360
- Registration Number
- NCT06863272
A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)
- Conditions
- Gastrointestinal Cancer
- Interventions
- Biological: Raludotatug Deruxtecan (R-DXd)
- First Posted Date
- 2025-03-07
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 160
- Registration Number
- NCT06864169
- Locations
- 🇺🇸
St. Vincent Healthcare Frontier Cancer Center ( Site 0347), Billings, Montana, United States
🇦🇷Fundación CORI para la Investigación y Prevención del Cáncer ( Site 0006), La Rioja, Argentina
🇨🇱FALP ( Site 0062), Santiago., Region M. De Santiago, Chile
A Study to Evaluate Opevesostat (MK-5684) in Male Participants With Moderate Hepatic Impairment (MK-5684-009)
- Conditions
- Hepatic ImpairmentHealthy Participants
- Interventions
- First Posted Date
- 2025-03-05
- Last Posted Date
- 2025-05-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 16
- Registration Number
- NCT06860243
- Locations
- 🇺🇸
Clinical Pharmacology of Miami ( Site 0002), Miami, Florida, United States
🇺🇸Texas Liver Institute ( Site 0001), San Antonio, Texas, United States